NVO:NYE-Novo Nordisk A/S (USD)

EQUITY | Drug Manufacturers - General | New York Stock Exchange

Last Closing

USD 107.2

Change

-0.43 (-0.40)%

Market Cap

USD 81.07B

Volume

5.22M

Analyst Target

USD 70.72
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Novo-Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes & obesity care and biopharmaceuticals.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-08 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
LLY Eli Lilly and Company

+0.90 (+0.11%)

USD 737.03B
JNJ Johnson & Johnson

-0.43 (-0.28%)

USD 380.12B
ABBV AbbVie Inc

-25.07 (-12.57%)

USD 352.54B
PFE Pfizer Inc

-0.48 (-1.80%)

USD 163.54B
BMY Bristol-Myers Squibb Company

+5.68 (+10.49%)

USD 121.33B
OGN Organon & Co

+0.05 (+0.31%)

USD 4.84B
GSK GlaxoSmithKline PLC ADR

+0.06 (+0.17%)

N/A
MRK Merck & Company Inc

-2.19 (-2.13%)

N/A
NVS Novartis AG ADR

-0.78 (-0.73%)

N/A

ETFs Containing NVO

OZEM Roundhill GLP-1 & Weight .. 17.60 % 0.00 %

-0.05 (0.13%)

USD 0.05B
THNR Amplify ETF Trust 13.45 % 0.00 %

+0.04 (+0.13%)

USD 4.67M
TTTX:CA Global X Innovative Bluec.. 8.05 % 0.00 %

+0.02 (+0.13%)

CAD 4.20M
BELT BlackRock Long-Term U.S. .. 5.72 % 0.00 %

+0.04 (+0.13%)

USD 0.01B
LIFE-B:CA Evolve Global Healthcare .. 5.27 % 0.00 %

-0.29 (0.13%)

N/A
PJIO PGIM ETF Trust 5.20 % 0.00 %

-0.02 (0.13%)

USD 0.01B
AADR AdvisorShares Dorsey Wrig.. 4.96 % 0.00 %

+0.20 (+0.13%)

USD 0.03B
PJBF 4.22 % 0.00 %

N/A

N/A
GINX SGI Enhanced Global Incom.. 3.16 % 0.00 %

-0.01 (0.13%)

N/A
SPWO SP Funds Trust 2.69 % 0.00 %

-0.14 (0.13%)

USD 0.03B
PTIN Pacer Trendpilot Internat.. 2.00 % 0.00 %

+0.06 (+0.13%)

USD 0.15B
APIE Trust For Professional Ma.. 1.51 % 0.00 %

-0.06 (0.13%)

USD 0.80B
AVSD American Century ETF Trus.. 1.36 % 0.00 %

+0.07 (+0.13%)

USD 0.14B
HFXI IQ 50 Percent Hedged FTSE.. 0.00 % 0.20 %

-0.34 (0.13%)

USD 0.80B
JPIN JPMorgan Diversified Retu.. 0.00 % 0.40 %

-0.09 (0.13%)

N/A
PPH VanEck Pharmaceutical ETF 0.00 % 0.36 %

-0.26 (0.13%)

USD 0.67B
RFAP 0.00 % 0.83 %

N/A

N/A
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

+0.04 (+0.13%)

CAD 0.05B
PDEV 0.00 % 0.00 %

N/A

N/A
SLIM 0.00 % 0.50 %

N/A

N/A
TLTD FlexShares Morningstar De.. 0.00 % 0.39 %

+0.02 (+0.13%)

USD 0.46B
DMRI 0.00 % 0.50 %

N/A

N/A
IMEA:LSE 0.00 % 0.00 %

N/A

N/A
BKIE BNY Mellon International .. 0.00 % 0.00 %

+0.01 (+0.13%)

USD 0.73B
LEAD-U:CA 0.00 % 0.00 %

N/A

N/A
DXIF:CA Dynamic Active Internatio.. 0.00 % 0.00 %

+0.12 (+0.13%)

CAD 4.84M
LEAD:CA Evolve Future Leadership .. 0.00 % 0.00 %

+0.77 (+0.13%)

CAD 0.01B
LEAD-B:CA Evolve Future Leadership .. 0.00 % 0.00 %

+0.26 (+0.13%)

CAD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -97.93% 10% F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.93% 10% F 1% F
Trailing 12 Months  
Capital Gain -97.88% 10% F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.88% 10% F 1% F
Trailing 5 Years  
Capital Gain -92.59% 11% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -92.59% 11% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain 37.88% 90% A- 91% A-
Dividend Return 39.54% 90% A- 90% A-
Total Return 1.66% 20% F 40% F
Risk Return Profile  
Volatility (Standard Deviation) 33.96% 10% F 30% F
Risk Adjusted Return 116.44% 80% B- 99% N/A
Market Capitalization 81.07B 86% B+ 100% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - General) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 14.90 50% 18%
Price/Book Ratio 30.41 57% 3%
Price / Cash Flow Ratio 4.58 100% 62%
Price/Free Cash Flow Ratio 25.51 57% 12%
Management Effectiveness  
Return on Equity 88.57% 100% 99%
Return on Invested Capital 70.15% 100% 99%
Return on Assets 22.80% 100% 100%
Debt to Equity Ratio 14.99% 86% 84%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.